Stephen H. Barnes, the Chief Financial Officer of Accolade, Inc. (NASDAQ:ACCD), recently sold shares of the company's common stock. According to a filing with the Securities and Exchange Commission, Barnes sold 123 shares on December 17 at a price of $3.432 per share, totaling $422. The transaction occurs as Accolade trades near its 52-week low, significantly below its peak of $15.36. InvestingPro analysis suggests the stock is currently undervalued. This transaction was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs). After this sale, Barnes holds 220,463 shares of Accolade's common stock.
Additionally, on December 16, Barnes acquired 415 shares of common stock through the conversion of RSUs, which did not involve a cash transaction. The RSUs were part of a vesting schedule tied to his continued service with the company.
In other recent news, Accolade Inc (NASDAQ:ACCD). has been a focal point for various analyst firms. Wells Fargo (NYSE:WFC) revised Accolade's price target down to $6.00, citing delayed deal closures impacting anticipated growth. Despite this, they maintain an Equal Weight rating on the stock. Similarly, Stephens, Canaccord Genuity, and Truist Securities adjusted their price targets for Accolade, while all maintaining Buy ratings. BofA Securities also revised their price target to $5.75, but sustained their Buy rating.
The company's recent financial performance has been strong, with second-quarter results for 2025 exceeding revenue expectations at $106.4 million and surpassing its adjusted EBITDA guidance. Accolade also confirmed its fiscal year 2025 revenue guidance between $460 million to $475 million and projected a positive adjusted EBITDA of $15 million to $20 million.
However, the company's revenue growth may be slower in fiscal year 2026 due to staggered launches. This is despite optimism from Accolade's management about a strong pipeline diversified across employers, health plans, and government segments. The company's successful management of marketing expenses and competitive edge in the expert medical opinion product market have been notable recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.